Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Johann S. de Bono, Nicholas J. Vogelzang et al.|The Lancet Oncology|2012Cited by 1.4k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant ChemotherapyRoland Seiler, Peter C. Black, H.A.D.M. Ashab et al.|European Urology|2017Cited by 793
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)Dana E. Rathkopf, Fred Saad, Matthew R. Smith et al.|European Urology|2014Cited by 273
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate CancerCameron Herberts, Alexander W. Wyatt, Andrew J. Murtha et al.|European Urology|2020Cited by 90